adverse events

Complications Associated with Offloading: Results of a Randomized Controlled Trial
Objective: To compare the frequency of adverse events between groups treated with total contact cast (TCC), instant total contact cast (iTCC), and removable cast walker (RCW). Methodology...
08/19/2021
News
Isatuximab Combination Effective in Myeloma and Soft-Tissue Plasmacytomas
06/22/2020
Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...
Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...
...
06/22/2020
Journal of Clinical Pathways
News
Venetoclax-Based Time-Limited Therapy Well Tolerated, Effective in CLL
06/10/2020
Zanubrutinib plus venetoclax and obinutuzumab is well tolerated and achieves rapid undetectable minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL), according to a presentation at the...
Zanubrutinib plus venetoclax and obinutuzumab is well tolerated and achieves rapid undetectable minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL), according to a presentation at the...
...
06/10/2020
Journal of Clinical Pathways
News
Real-World Costs of Adverse Events After First-Line Treatment of Metastatic NSCLC
06/09/2020
Real-world patients with metastatic non-small cell lung cancer (NSCLC) who receive first-line immunotherapy are less likely to incur adverse event-related costs than those treated with first-line cytotoxic...
Real-world patients with metastatic non-small cell lung cancer (NSCLC) who receive first-line immunotherapy are less likely to incur adverse event-related costs than those treated with first-line cytotoxic...
...
06/09/2020
Journal of Clinical Pathways
News
Effective, Less Toxic Treatment Option Identified for Aggressive B-Cell Lymphoma
05/29/2020
Risk-adapted dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) therapy is effective and well tolerated in adults with Burkitt lymphoma regardless of age or...
Risk-adapted dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) therapy is effective and well tolerated in adults with Burkitt lymphoma regardless of age or...
...
05/29/2020
Journal of Clinical Pathways
News
Hypercalcemia as a Biomarker for Aggressive Disease in Patients With B-Cell Lymphoma
05/13/2020
For patients with diffuse large B-cell lymphoma (DLBCL), presence of hypercalcemia at diagnosis correlates with negative prognostic factors and a short diagnosis-to-treatment interval, according to a retrospective...
For patients with diffuse large B-cell lymphoma (DLBCL), presence of hypercalcemia at diagnosis correlates with negative prognostic factors and a short diagnosis-to-treatment interval, according to a retrospective...
For...
05/13/2020
Journal of Clinical Pathways
News
High Risk of Preventable and Mitigable Adverse Events in Cancer Care
08/22/2017
JCP Editors
Researchers have identified a significant burden of adverse events across the cancer care continuum, including preventable or mitigable events, according to a study published in Cancer (online August 17, 2017;...
Researchers have identified a significant burden of adverse events across the cancer care continuum, including preventable or mitigable events, according to a study published in Cancer (online August 17, 2017;...
...
08/22/2017
Journal of Clinical Pathways
Research in Review
Trastuzumab-Related Cardiotoxicity Prevented In Patients With Breast Cancer
11/30/2016
JCP Editors
Two kinds of heart medications, angiotensin-converting enzyme (ACE) inhibitors and beta blockers, can help to prevent a decline in heart function from breast cancer treatment, according to new research published in...
Two kinds of heart medications, angiotensin-converting enzyme (ACE) inhibitors and beta blockers, can help to prevent a decline in heart function from breast cancer treatment, according to new research published in...
Two...
11/30/2016
Journal of Clinical Pathways
Algorithm Improves Adverse Event Response for Patients Receiving Immunotherapies
05/02/2016
JCP Editors
A standard algorithm created by a nurse-led collaborative team helped clinicians better assess and manage adverse events in patients receiving immunotherapy for cancer, according to an oral presentation at the...
A standard algorithm created by a nurse-led collaborative team helped clinicians better assess and manage adverse events in patients receiving immunotherapy for cancer, according to an oral presentation at the...
A...
05/02/2016
Journal of Clinical Pathways
Original Contribution
Effect of Prior Aspirin Treatment on Patients With Acute Coronary Syndromes: Insights From the PROSPECT Study
07/15/2015
Prior aspirin treatment is considered a risk factor for adverse outcomes in ACS patients. This PROSPECT trial analysis of patients with versus without aspirin pretreatment indicates that aspirin pretreatment was not an independent predictor...
Prior aspirin treatment is considered a risk factor for adverse outcomes in ACS patients. This PROSPECT trial analysis of patients with versus without aspirin pretreatment indicates that aspirin pretreatment was not an independent predictor...
Prior aspirin treatment is...
07/15/2015
Journal of Invasive Cardiology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use